Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Other Accumulated Expenses: 2009-2025

Historic Other Accumulated Expenses for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $78.3 million.

  • UNITED THERAPEUTICS's Other Accumulated Expenses fell 2.25% to $78.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.3 million, marking a year-over-year decrease of 2.25%. This contributed to the annual value of $93.6 million for FY2024, which is 31.83% up from last year.
  • According to the latest figures from Q3 2025, UNITED THERAPEUTICS's Other Accumulated Expenses is $78.3 million, which was down 17.67% from $95.1 million recorded in Q2 2025.
  • UNITED THERAPEUTICS's 5-year Other Accumulated Expenses high stood at $154.5 million for Q1 2025, and its period low was $24.8 million during Q2 2021.
  • Its 3-year average for Other Accumulated Expenses is $83.9 million, with a median of $78.3 million in 2025.
  • In the last 5 years, UNITED THERAPEUTICS's Other Accumulated Expenses slumped by 47.58% in 2021 and then spiked by 227.20% in 2024.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's Other Accumulated Expenses stood at $28.4 million in 2021, then grew by 14.44% to $32.5 million in 2022, then skyrocketed by 118.46% to $71.0 million in 2023, then soared by 31.83% to $93.6 million in 2024, then dropped by 2.25% to $78.3 million in 2025.
  • Its Other Accumulated Expenses stands at $78.3 million for Q3 2025, versus $95.1 million for Q2 2025 and $154.5 million for Q1 2025.